About Us

Universal Biosensors (UBI) is a medical diagnostics company focused on the research, development and manufacture of diagnostic test systems for point-of-care (POC) professional and home use. The point-of-care diagnostic market is worth US$15 billion a year and growing.

UBI has partnered with global healthcare company Siemens Healthcare Diagnostics to develop the Xprecia StrideTM blood coagulation analyser, launched in December 2014, to help patients taking the anticoagulant drug Warfarin manage their medication.

UBI has also developed a blood glucose monitoring product that is being commercialised globally by LifeScan, Inc. (a Johnson & Johnson company) under the OneTouch® Verio® brand. 

UBI's innovative electrochemical sensor platform is being applied to a range of other medical diagnostic applications.

The company is listed on the Australian Securities Exchange under the ticker "UBI", and operates from its manufacturing and R&D facility in Melbourne, Australia.


Read more about Corporate Overview & Strategy